Exhibit 99.1 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Program Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- PCV Franchise Infant Indication: -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of ...

Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Andrew Guggenhime - President and Chief Financial Officer Grant Pickering - Chief Executive Officer, Director and Founder Jim Wassil - Executive Vice President and Chief Operating Officer Conference Call Participants Jason Gerberry - Bank of America Roger Song - Jefferies Dave Risinger - Leerink Partners Umer Raffat - Evercore Seamus Fernandez - Guggenheim Louise Chen - Cantor Fitzgerald Joseph Str ...

February 27, 2024 Forward-Looking Statements These forward-looking statements are based on Vaxcyte's current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte's product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities; potential ...

FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 001-39323 VAXCYTE, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of inco ...

Exhibit 99.1 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- Enrollment in V ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number: 001-39323 VAXCYTE, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdictio ...

| --- | --- | --- | --- | --- | |---------------------------------------|-------|-------|-------|-------| | | | | | | | 4Q & FY 2022 | | | | | | Financial Results and Business Update | | | | | | | | | | | February 27, 2023 VAXCYTE Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte's vaccine candidat ...

Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Andrew Guggenhime - President and Chief Financial Officer Grant Pickering - Chief Executive Officer Jim Wassil - Executive Vice President and Chief Operating Officer Jeff Fairman - Vice President, Research Conference Call Participants Jason Gerberry - Bank of America Roger Song - Jefferies David Risinger - SVB Seamus Fernandez - Guggenheim. Jonathan Miller - Evercore Louise Chen - Cantor Joseph Str ...